Abstract
Brunner's glands (duodenal glands) in humans are located mainly in the two proximal thirds of the duodenum. They are known to produce and secrete mucin. In recent years, human Brunner's glands have also been shown to express immunoreactivity toward epidermal growth factor-urogastrone (EGF-uro) and lysozyme. These proteins are considered to have a protective function within the gastrointestinal canal. Human pancreatic secretory trypsin inhibitor (PSTI) was recently identified in Brunner's glands. This present study was done by an immunohistochemical method, using monospecific polyclonal antibodies against human PSTI and human lysozyme, respectively. McManus/Alcian blue mucin staining was used to clarify the distribution of mucin. We found immunoreactive PSTI (irPSTI) in seven out of ten specimens. Lysozyme and mucin were present in all ten. While virtually all cells were stained for lysozyme and mucin, irPSTI was restricted to separate lobules and to cells in the ducts.
Similar content being viewed by others
References
Kazal LA, Spicer DS, Brahinsky RA. Isolation of a crystalline trypsin inhibitor-anticoagulant protein from pancreas. J Am Chem Soc 1948;70:3034–3040.
Fritz H, Hüller I, Wiedemann M, Werle E. Zur Chemie und Physiologie der spezifischen Trypsininhibitoren aus den Bauchspecheldrusen von Rind, Hund, Schwein und Mensch. Hoppe-Seyler's Z Physiol Chem 1967;348:405–418.
Matsuda K, Ogawa M, Murata A, et al. Elevation of serum immunoreactive pancreatic secretory trypsin inhibitor contents in various malignant diseases. Res Commun Chem Pathol Pharmacol 1983;40:301–305.
Borgström A, Wehlin L. Correlation between serum concentrations of three specific exocrine pancreatic proteins and pancreatic duct morphology at ERCP examinations. Scand J Gastroenterol 1984;19:220–227.
Bohe M. Immunoreactive pancreatic secretory trypsin inhibitor in sera from patients with acute ulcerative colitis. Res Exp Med 1987;187:55–58.
Lasson Å, Borgstrom A, Ohlsson K. Elevated PSTI levels during severe inflammatory disease, renal insufficiency and after different surgical procedures. Scand J Gastroenterol 1986;21:1275–1280.
Matsuda K, Ogawa M, Shibata T. Postoperative elevation of serum pancreatic secretory trypsin inhibitor. Am J Gastroenterol 1985;80:694–698.
Shibata T, Ogawa M, Takata N, et al. Elevation of serum pancreatic secretory trypsin inhibitor following serious injury. Resuscitation 1988;16:163–168.
Halila H, Huhtala ML, Schröder T, et al. Pancreatic secretory trypsin-like immunoreactivity in pancreatectomized patients. Clin Chim Acta 1985;153:209–216.
Huhtala M-L, Pesonen K, Kalkkinen N, Stenman U-H. Purification and Characterization of a tumor-associated trypsin inhibitor from the urine of patient with ovarian cancer. J Biol Chem 1982;257:13713–13716.
Halila H, Huhtala M-L, Haglund C, et al. Tumour-associated trypsin inhibitor (TATI) in human ovarian cyst fluid. Comparison with CA125 and CEA. Br J Cancer 1987;56:153–156.
Bohe M, Lindstrom CG, Ohlsson K. Varying occurrence of gastroduodenal immunoreactive pancreatic secretory trypsin inhibitor. J Clin Pathol 1987;40:1345–1348.
Bohe M, Lindstrom C, Ohlsson K. Immunoreactive pancreatic secretory trypsin inhibitor in gastrointestinal mucosa. Adv Exp Med Biol 1988;240:101–105.
Freeman TC, Playford RJ, Quinn C, et al. Pancreatic secretory trypsin inhibitor in gastrointestinal mucosa and gastric juice. Gut 1990;31:1318–1323.
Bohe M, Borgstrom A, Lindstrom C, Ohlsson K. Pancreatic endoproteases and pancreatic secretory trypsin inhibitor immuno-reactivity in human Paneth cells. J Clin Pathol 1986;39:786–793.
Fukayama M, Hayashi Y, Koike M, et al. Immunohistochemical localization of pancreatic secretory trypsin inhibitor in fetal and adult pancreatic and extrapancreatic tissues. J Histochem Cytochem 1986;34:227–235.
Higashiyama M, Monden T, Ogawa M, et al. Immunohistochemical study on pancreatic secretory trypsin inhibitor (PSTI) in gastric carcinomas. Am J Clin Pathol 1990;93:8–13.
Bohe H, Bohe M, Lindström C, Ohlsson K. Immunohistochemical demonstration of pancreatic secretory trypsin inhibitor in normal and neoplastic colonic mucosa. J Clin Pathol 1990;43:901–904.
Bohe H, Bohe M, Lindstrom C, Ohlsson K. Immunoreactive pancreatic secretory trypsin inhibitor in normal, inflammatory and neoplastic gallbladders. Gastroenterol Jpn 1991;26:95–98.
Ogawa M, Tsushima T, Ohba Y, et al. Stimulation of DNA synthesis in human fibroblasts by human pancreatic secretory trypsin inhibitor. Res Commun Chem Pathol Pharm 1985;50:155–158.
Freeman TC, Curry B, Calam J, Woodburn J. Pancreatic secretory trypsin inhibitor stimulates the growth of rat pancreatic carcinoma cells. Gastroenterology 1990;99:1414–1420.
McKeehan WL, Sakagami Y, Hoshi H, McKeehan K. Two apparent human endothelial cell growth factors from human hepatoma cells are tumor-associated proteinase inhibitors. J Biol Chem 1986;261:5378–5383.
Sternberger LA, Hardy PH Jr, Cuculis JJ, Meyer HG. The unlabelled antibody enzyme method of immunochemistry. Preparations and properties of soluble antigen-antibody complex (horseradish peroxidase-antihorseradish peroxidase) and its use in identification of spirochetes. J Histochem Cytochem 1970;18:315–333.
Fryksmark U, Ohlsson K, Polling Å, Tegner H. Distribution of antileukoprotease and characterization of human antileukoprotease in serum. Ann Otol Rhinol Laryngol 1982;91:268–271.
Eddeland A, Ohlsson K. Purification and immunochemical quantitation of human pancreatic secretory trypsin inhibitor. Scand J Clin Lab Invest 1978;38:261–267.
Kittas C, Aroni K, Kotsis L, Papadimitriou S. Distribution of lysozyme, al-antichymotrypsin and al-antitrypsin in adenocarcinomas of the stomach and large intestine. Virchows Arch [A] 1982;398:139–147.
Kittas C, Aroni K, Matani A, Papadimitriou C. Immuno-cytochemical demonstration of al-antitrypsin and al-antichymo-trypsin in human gastrointestinal tract. Hepato-gastroenterology 1982;29:275–277.
Klockars M, Reitamo S. Tissue distribution of lysozyme in man. J Histochem Cytochem 1975;23:932–940.
Saito H, Kasajima T, Masuda A, Imai Y, Ishikawa M. Lysozyme localization in human gastric and duodenal epithelium. Cell Tissue Res 1988;251:307–313.
Vaines K, Brandtzaeg P, Elgjo K, Stave R. Specific and non-specific humoral defense factors in the epithelium of normal and inflamed gastric mucosa. Gastroenterology 1984;86:402–412.
Wittekind C, Wachner R, Henke W, von Kleist S. Localization of CEA, HCG, lysozyme, alpha-1-antitrypsin, and alpha-1-antichymotrypsin in gastric cancer and prognosis. Virchows Arch [A] 1986;409:715–724.
Selested M, Martinez R. Lysozyme: Primary bactericidin in human plasma serum active againstBacillus subtilis. Infect Immun 1978;20:782–791.
Reitamo S, Reitamo J, Sipponen P, Klockars M. The distribution of lysozyme in human gastric mucosa in inflammatory and neoplastic disorders. Acta Pathol Microbiol Scand 1979;87[Sect. A]:451–456.
Erlandsen SL, Parson JA. Immunochemical localization of lysozyme in the small intestine of man using the unlabeled antibody enzyme method. J Histochem Cytochem 1973;21:405–406.
Mason DY, Taylor CR. The distribution of muramidase (lysozyme) in human tissues. J Clin Pathol 1975;28:124–132.
Heitz PU, Wegman W. Identification of neoplastic Paneth cells in an adenocarcinoma of the stomach using lysozyme as a marker, and electron microscopy. Virchows Arch [A] 1980;386:107–116.
Heitz PU, Kasper M, van Norden S, et al. Immunohistochemical localisation of urogastrone to human duodenal and submandibular gland. Gut 1978;19:408–413.
Kasselberg AG, Orth D, Gray M, Stahlman M. Immuno-cytochemical localization of human epidermal growth factor/ urogastrone in several human tissues. J Histochem Cytochem 1985;33:315–322.
Poulsen SS, Nexo E, Skov Olsen P, et al. Immunohistochemical localization of epidermal growth factor in rat and man. Histochemistry 1986;85:389–394.
Elder JB, Ganguli PC, Gillespie IE, et al. Effect of urogastrone on gastric secretion in normal subjects. Gut 1975:16:887–893.
Elder JB, Ganguli PC, Gillespie IE, et al. Effect of urogastrone in the Zollinger-Ellison syndrome. Lancet 1975;II:424–427.
Gillespie IE, Elder JB, Ganguli PC, et al. Initial observations on the inhibitory action of urogastrone on gastric secretory response: in man. Gut 1974;15:337.
Koffman CG, Elder JB, Ganguli PC, et al. Effect of urogastrone on gastric secretion and serum gastrin concentration in patients with duodenal ulceration. Gut 1982;23:951–956.
Konturek SJ, Bielanski W, Konturek JW, et al. Release and action of epidermal growth factor on gastric secretion in humans. Scand J Gastroenterol 1989;24:485–492.
Walker-Smith J. Intravenous epidermal growth factor/urogastrone increases small-intestinal cell proliferation in congenital microvillous atrophy. Lancet 1985:11:1239–1240.
Wright NA, Pike C, Elia G. Ulceration induces a novel epidermal growth factor-secreting cell lineage in human gastrointestinal mucosa. Digestion 1990;46[Suppl 2]:125–133.
Wright NA, Pike C, Elia G. Induction of a novel epidermal growth factor-secreting cell in human gastrointestinal stem cells. Nature 1990;343:82–85.
Cohen S, Carpenter G. Human epidermal growth factor: Isolation and chemical and biological properties. Proc Natl Acad Sci USA 1975;72:1317–1321.
Niinobu T, Ogawa M, Shibata T, et al. Specific binding of human pancreatic secretory trypsin inhibitor to various cultured cells. Res Commun Chem Pathol Pharmacol 1986;53:245–248.
Grossman MI. The glands of Brunner. Physical Rev 1958;38:675–690.
Konturek JW, Bielanski W, Konturek SJ, et al. Distribution and release of epidermal growth factor in man. Gut 1989;30:1194–1200.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bohe, H., Bohe, M., Lindström, C. et al. Pancreatic secretory trypsin inhibitor in human Brunner's glands. J Gastroenterol 30, 90–95 (1995). https://doi.org/10.1007/BF01211381
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01211381